Advertisement

Allergan, Pfizer call off proposed $160B merger

By Associated Press  |  April 06, 2016

The biggest U.S.-based drugmaker, Pfizer, will stay put thanks to aggressive new Treasury Department rules that succeeded in discouraging Pfizer's plan to acquire rival Allergan and move to Ireland—on paper—to reduce its tax bill.

FDA approves biosimilar of J&J's money maker Remicade

By Associated Press  |  April 05, 2016

The approval of Inflectra Tuesday is only the second time that the FDA has approved a quasi-generic version of a biotech drug for the U.S. market. Remicade, a medicine for inflammatory diseases, had $6.56 billion in sales last year.

Allergan shares tumble on new tax inversion rules

By Associated Press  |  April 05, 2016

Allergan's stock is down nearly 20% in pre-market Tuesday trading after the U.S. announced an aggressive push in its campaign to shut down so-called tax inversions by American companies.

Pfizer adds $784.6M charge for Protonix deal to Q4 results

By Associated Press  |  February 16, 2016

Drugmaker Pfizer swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its former blockbuster heartburn pill.

Senator scrutinizes pharma links on government pain panel

Senator scrutinizes pharma links on government pain panel

By Associated Press  |  February 08, 2016

Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.

Pfizer earnings fall but top Wall Street 4Q forecasts

By Associated Press  |  February 02, 2016

Pfizer's fourth-quarter profit fell by half due to higher costs for production, administration and restructuring, but new revenue from an acquisition helped the world's second-biggest drugmaker beat Wall Street expectations.

Dealmaking keeps up heady pace

By Melanie Evans  |  January 23, 2016

Last year ended as frenzied as it began for healthcare dealmakers. Globally, merger and acquisition activity reached record volume in 2015, and the value of global healthcare deals increased 66% last year to $723.7 billion, according to Dealogic.

Drugmakers commit to fight against antibiotic resistance

By Steven Ross Johnson  |  January 21, 2016

More than 80 pharmaceutical, diagnostic and biotech firms are calling for increased government investment of new antibiotic drugs to address the growing threat posed by drug-resistant infections coupled with dwindling innovation of new treatments.

First-of-a-kind drug approvals continued rise in 2015

By Associated Press  |  January 04, 2016

Approvals for first-of-a-kind drugs climbed last year, pushing the annual tally of new U.S. drugs to its highest level in 19 years. The figures reflect a focus on drugs for rare and hard-to-treat diseases, which often come with streamlined reviews, extra patent protections and higher price tags.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.